开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
据叙利亚阿拉伯通讯社(SANA):也门政府军周二表示,在与胡塞武装发生冲突后,已完全控制位于南部塔伊兹省的战略要地卡尔凡山(Mount Qarfan)。
2026-09-23
据叙利亚阿拉伯通讯社(SANA):也门政府军周二表示,在与胡塞武装发生冲突后,已完全控制位于南部塔伊兹省的战略要地卡尔凡山(Mount Qarfan)。
返回
其他消息
2026-09-23
Tencent said it has partnered with Leapmotor to deploy its all-scenario AI desktop WorkBuddy. WorkBuddy supports local file handling, multi-task and multi-agent parallel operation, and a Skills and MCP ecosystem; it has been rolled out across Leapmotor’s vehicle development, intelligent driving, connected car, procurement and supply‑chain, and audit functions.
Tencent said it has partnered with Leapmotor to deploy its all-scenario AI desktop WorkBuddy. WorkBuddy supports local file handling, multi-task and multi-agent parallel operation, and a Skills and MCP ecosystem; it has been rolled out across Leapmotor’s vehicle development, intelligent driving, connected car, procurement and supply‑chain, and audit functions.
2026-09-23
Novo Nordisk said it is open to upgrading its U.S. listing — potentially replacing its American depositary receipts with a direct New York listing — as the Danish maker of weight‑loss drugs seeks greater U.S. visibility. Asked whether the company would consider listing shares directly on the NYSE instead of ADRs, the CEO said he saw advantages and would not rule it out but added the company is not currently studying the option. He noted rival AstraZeneca made a similar move earlier this year.
Novo Nordisk said it is open to upgrading its U.S. listing — potentially replacing its American depositary receipts with a direct New York listing — as the Danish maker of weight‑loss drugs seeks greater U.S. visibility. Asked whether the company would consider listing shares directly on the NYSE instead of ADRs, the CEO said he saw advantages and would not rule it out but added the company is not currently studying the option. He noted rival AstraZeneca made a similar move earlier this year.
Chat with us
, powered by
LiveChat